neoplasm transplantation

Summary

Summary: Experimental transplantation of neoplasms in laboratory animals for research purposes.

Top Publications

  1. ncbi Identification of human brain tumour initiating cells
    Sheila K Singh
    The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children and University of Toronto, 555 University Avenue, Toronto, M5G 1X8, Canada
    Nature 432:396-401. 2004
  2. ncbi A human colon cancer cell capable of initiating tumour growth in immunodeficient mice
    Catherine A O'Brien
    Division of Cell and Molecular Biology, University Health Network, Toronto, Ontario, M5G 1L7, Canada
    Nature 445:106-10. 2007
  3. ncbi Identification and expansion of human colon-cancer-initiating cells
    Lucia Ricci-Vitiani
    Department of Hematology and Oncology, Istituto Superiore di Sanita, Viale Regina Elena 299, Rome 00161, Italy
    Nature 445:111-5. 2007
  4. ncbi Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
    D Bonnet
    Department of Genetics, Research Institute, Hospital for Sick Children, University of Toronto, Ontario, Canada
    Nat Med 3:730-7. 1997
  5. ncbi Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells
    Michael F Clarke
    Stanford University School of Medicine, Stanford, California, USA
    Cancer Res 66:9339-44. 2006
  6. pmc Guidelines for the welfare and use of animals in cancer research
    P Workman
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Br J Cancer 102:1555-77. 2010
  7. pmc Phenotypic characterization of human colorectal cancer stem cells
    Piero Dalerba
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
    Proc Natl Acad Sci U S A 104:10158-63. 2007
  8. pmc Efficient tumour formation by single human melanoma cells
    Elsa Quintana
    Howard Hughes Medical Institute, Life Sciences Institute, Department of Internal Medicine, and Center for Stem Cell Biology, University of Michigan, Ann Arbor, Michigan 48109 2216, USA
    Nature 456:593-8. 2008
  9. pmc Identification of cells initiating human melanomas
    Tobias Schatton
    Transplantation Research Center, Children s Hospital Boston and Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nature 451:345-9. 2008
  10. ncbi Significance of CD90+ cancer stem cells in human liver cancer
    Zhen Fan Yang
    Center for Cancer Research and Department of Surgery, The University of Hong Kong, Pokfulam, Hong Kong, China
    Cancer Cell 13:153-66. 2008

Research Grants

Detail Information

Publications313 found, 100 shown here

  1. ncbi Identification of human brain tumour initiating cells
    Sheila K Singh
    The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children and University of Toronto, 555 University Avenue, Toronto, M5G 1X8, Canada
    Nature 432:396-401. 2004
    ....
  2. ncbi A human colon cancer cell capable of initiating tumour growth in immunodeficient mice
    Catherine A O'Brien
    Division of Cell and Molecular Biology, University Health Network, Toronto, Ontario, M5G 1L7, Canada
    Nature 445:106-10. 2007
    ....
  3. ncbi Identification and expansion of human colon-cancer-initiating cells
    Lucia Ricci-Vitiani
    Department of Hematology and Oncology, Istituto Superiore di Sanita, Viale Regina Elena 299, Rome 00161, Italy
    Nature 445:111-5. 2007
    ..We conclude that colorectal cancer is created and propagated by a small number of undifferentiated tumorigenic CD133+ cells, which should therefore be the target of future therapies...
  4. ncbi Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
    D Bonnet
    Department of Genetics, Research Institute, Hospital for Sick Children, University of Toronto, Ontario, Canada
    Nat Med 3:730-7. 1997
    ..The SL-ICs were able to differentiate in vivo into leukemic blasts, indicating that the leukemic clone is organized as a hierarchy...
  5. ncbi Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells
    Michael F Clarke
    Stanford University School of Medicine, Stanford, California, USA
    Cancer Res 66:9339-44. 2006
  6. pmc Guidelines for the welfare and use of animals in cancer research
    P Workman
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Br J Cancer 102:1555-77. 2010
    ....
  7. pmc Phenotypic characterization of human colorectal cancer stem cells
    Piero Dalerba
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
    Proc Natl Acad Sci U S A 104:10158-63. 2007
    ..These results validate the stem cell working model in human CRC and provide a highly robust surface marker profile for CRC stem cell isolation...
  8. pmc Efficient tumour formation by single human melanoma cells
    Elsa Quintana
    Howard Hughes Medical Institute, Life Sciences Institute, Department of Internal Medicine, and Center for Stem Cell Biology, University of Michigan, Ann Arbor, Michigan 48109 2216, USA
    Nature 456:593-8. 2008
    ..Modifications to xenotransplantation assays can therefore dramatically increase the detectable frequency of tumorigenic cells, demonstrating that they are common in some human cancers...
  9. pmc Identification of cells initiating human melanomas
    Tobias Schatton
    Transplantation Research Center, Children s Hospital Boston and Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nature 451:345-9. 2008
    ..Identification of tumour-initiating cells with enhanced abundance in more advanced disease but susceptibility to specific targeting through a defining chemoresistance determinant has important implications for cancer therapy...
  10. ncbi Significance of CD90+ cancer stem cells in human liver cancer
    Zhen Fan Yang
    Center for Cancer Research and Department of Surgery, The University of Hong Kong, Pokfulam, Hong Kong, China
    Cancer Cell 13:153-66. 2008
    ..Differential gene expression profiles were identified in the CD45(-)CD90+ and CD45(-)CD90(-) cells isolated from tissue and blood samples from liver cancer patients and controls...
  11. pmc The increasing complexity of the cancer stem cell paradigm
    Jeffrey M Rosen
    Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    Science 324:1670-3. 2009
    ....
  12. ncbi Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic
    Lubna Patrawala
    Department of Carcinogenesis, Science Park Research Division, The University of Texas M D Anderson Cancer Center, Smithville, Texas 78957, USA
    Cancer Res 65:6207-19. 2005
    ....
  13. pmc Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells
    Zhizhong Li
    Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Cell 15:501-13. 2009
    ..Our results demonstrate that GSCs differentially respond to hypoxia with distinct HIF induction patterns, and HIF2alpha might represent a promising target for antiglioblastoma therapies...
  14. ncbi Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells
    L Patrawala
    Department of Carcinogenesis, The University of Texas MD Anderson Cancer Center, Science Park Research Division, Smithville, 78957, USA
    Oncogene 25:1696-708. 2006
    ..Altogether, our results suggest that the CD44(+) PCa cell population is enriched in tumorigenic and metastatic progenitor cells...
  15. pmc Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271
    Alexander D Boiko
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, Stanford University School of Medicine, Stanford, California 94304 5542, USA
    Nature 466:133-7. 2010
    ....
  16. ncbi A tumorigenic subpopulation with stem cell properties in melanomas
    Dong Fang
    Program of Molecular and Cellular Oncogenesis, The Wistar Institute and Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, PA 19104, USA
    Cancer Res 65:9328-37. 2005
    ..Based on these findings, we propose that melanomas can contain a subpopulation of stem cells that contribute to heterogeneity and tumorigenesis. Targeting this population may lead to effective treatments for melanomas...
  17. pmc Cancerous stem cells can arise from pediatric brain tumors
    Houman D Hemmati
    Division of Biology 139 74, California Institute of Technology, Pasadena, CA 91125, USA
    Proc Natl Acad Sci U S A 100:15178-83. 2003
    ..This finding may have important implications for treatment by means of specific targeting of stem-like cells within brain tumors...
  18. ncbi Lysyl oxidase is essential for hypoxia-induced metastasis
    Janine T Erler
    Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California 94305, USA
    Nature 440:1222-6. 2006
    ..Furthermore, LOX may be required to create a niche permissive for metastatic growth. Our findings indicate that LOX is essential for hypoxia-induced metastasis and is a good therapeutic target for preventing and treating metastases...
  19. pmc A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer
    Theresa A DiMeo
    Department of Anatomy and Cellular Biology, Sackler School, Tufts University School of Medicine, Boston, MA 02111, USA
    Cancer Res 69:5364-73. 2009
    ..Collectively, these results provide a molecular link between self-renewal, EMT, and metastasis in basal-like breast cancers...
  20. ncbi Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line
    Jing Wang
    State Key Laboratory of Oncology in Southern China and Department of Experimental Research, Sun Yat sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510 060, P R China
    Cancer Res 67:3716-24. 2007
    ..Taken together, our data shed light on tumorigenesis and therapeutic-resistant mechanisms, which are helpful for developing novel targets for effective clinical treatment of NPC...
  21. ncbi Enhancement of antitumor immunity by CTLA-4 blockade
    D R Leach
    Cancer Research Laboratory, University of California, Berkeley, CA 94720, USA
    Science 271:1734-6. 1996
    ..These results suggest that blockade of the inhibitory effects of CTLA-4 can allow for, and potentiate, effective immune responses against tumor cells...
  22. ncbi Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation
    Benjamin W Purow
    Neuro Oncology Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Cancer Res 65:2353-63. 2005
    ..Notch-1 and its ligands may present novel therapeutic targets in the treatment of glioma...
  23. ncbi Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma
    Shih Hwa Chiou
    Institutes of Oral Biology, Traditional Medicine, and Anatomy and Cell Biology, National Yang Ming University, Taiwan, People s Republic of China
    Clin Cancer Res 14:4085-95. 2008
    ..Identification and characterization of CSC from OSCC facilitates the monitoring, therapy, or prevention of OSCC...
  24. pmc GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model
    Hosein Kouros-Mehr
    Department of Anatomy, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143 0452, USA
    Cancer Cell 13:141-52. 2008
    ..Rather, malignant progression occurred with an expanding GATA-3-negative tumor cell population. These data indicate that GATA-3 regulates tumor differentiation and suppresses tumor dissemination in breast cancer...
  25. ncbi Side population cells in human cancers
    Colleen Wu
    Program in Developmental and Stem Cell Biology, Hospital for Sick Children, University of Toronto, Toronto Medical Discovery Tower, East Tower, 101 College Street, Toronto, Ont, Canada M5G 1L7
    Cancer Lett 268:1-9. 2008
    ..Dye exclusion is a valuable technique as it identifies a unique population of cells with stem-like characteristics...
  26. pmc CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis
    Siddhartha Jaiswal
    Ludwig Center at Stanford, Stanford Cancer Center, Department of Pathology, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
    Cell 138:271-85. 2009
    ..We conclude that CD47 upregulation is an important mechanism that provides protection to normal HSCs during inflammation-mediated mobilization, and that leukemic progenitors co-opt this ability in order to evade macrophage killing...
  27. pmc Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma
    Eli E Bar
    Johns Hopkins University School of Medicine, Department of Pathology, 720 Rutland Avenue, Ross Building 558, Baltimore, Maryland 21205, USA
    Stem Cells 25:2524-33. 2007
    ..Disclosure of potential conflicts of interest is found at the end of this article...
  28. pmc Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line
    Toru Kondo
    Department of Cell Fate Modulation, Institute of Molecular Embryology and Genetics, Kumamoto University, 2 2 1 Honjo, Kumamoto 860 0811, Japan
    Proc Natl Acad Sci U S A 101:781-6. 2004
    ..We propose that many cancer cell lines contain a minor subpopulation of stem cells that is enriched in an SP, can be maintained indefinitely in culture, and is crucial for their malignancy...
  29. ncbi Mouse models of advanced spontaneous metastasis for experimental therapeutics
    Giulio Francia
    The Molecular and Cellular Biology Research, Sunnybrook Health Science Centre, Toronto, Ontario M4N 3M5, Canada
    Nat Rev Cancer 11:135-41. 2011
    ....
  30. pmc Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors
    Pankaj Agarwalla
    Department of Neurosurgery, Massachusetts General Hospital, Boston, MA 02114, USA
    J Immunother 35:385-9. 2012
    ..Sequential immunotherapy with GM-CSF-expressing irradiated glioma cells and CTLA-4 blockade synergistically prolongs survival in mice bearing established intracranial gliomas...
  31. ncbi PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
    Yoichi Nagata
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Cell 6:117-27. 2004
    ..Thus, PTEN deficiency is a powerful predictor for trastuzumab resistance. Additionally, PI3K inhibitors rescued PTEN loss-induced trastuzumab resistance, suggesting that PI3K-targeting therapies could overcome this resistance...
  32. ncbi Malignant transformation in a nontumorigenic human prostatic epithelial cell line
    S W Hayward
    Department of Urology, University of California San Francisco, San Francisco, CA 94143, USA
    Cancer Res 61:8135-42. 2001
    ..The cells continued to express SV40T antigen. These cell strains, which are all derived from a common nontumorigenic progenitor, represent a useful resource for examining genetic and phenotypic changes during carcinogenesis...
  33. ncbi CXCR4 regulates growth of both primary and metastatic breast cancer
    Matthew C P Smith
    Molecular Imaging Center, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, Missouri, USA
    Cancer Res 64:8604-12. 2004
    ..These data indicate that CXCR4 is required to initiate proliferation and/or promote survival of breast cancer cells in vivo and suggest that CXCR4 inhibitors will improve treatment of patients with primary and metastatic breast cancer...
  34. pmc Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis
    Maria I Harrell
    Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Department of Comparative Medicine, University of Washington, 1100 Fairview Ave N, MS C2 023, P O Box 19024, Seattle, WA 98109, USA
    Am J Pathol 170:774-86. 2007
    ..Lymph node lymphangiogenesis and increased lymph flow through tumor-draining lymph nodes may actively promote metastasis via the lymphatics...
  35. ncbi Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
    Antoine E Karnoub
    Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA
    Nature 449:557-63. 2007
    ..Collectively, these data demonstrate that the tumour microenvironment facilitates metastatic spread by eliciting reversible changes in the phenotype of cancer cells...
  36. ncbi Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis
    Jing Yang
    Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, Massachusetts 02142, USA
    Cell 117:927-39. 2004
    ..These results establish a mechanistic link between Twist, EMT, and tumor metastasis...
  37. pmc Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells
    Keith Syson Chan
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA 94304 5542, USA
    Proc Natl Acad Sci U S A 106:14016-21. 2009
    ..Blockade of CD47 by a mAb resulted in macrophage engulfment of bladder cancer cells in vitro. In summary, we have identified a T-IC subpopulation with potential prognostic and therapeutic value for invasive bladder cancer...
  38. ncbi Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region
    Fumihiko Ishikawa
    Research Unit for Human Disease Models, RIKEN Research Center for Allergy and Immunology, 1 7 22 Suehiro cho Tsurumi ku, Yokohama 230 0045, Japan
    Nat Biotechnol 25:1315-21. 2007
    ..These results indicate the potential utility of this AML xenograft model in the development of novel therapeutic strategies targeted at LS cells...
  39. pmc The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells
    Li Bing Song
    State Key Laboratory of Oncology in South China, Sun Yat sen University Cancer Center, Guangzhou, People s Republic of China
    J Clin Invest 119:3626-36. 2009
    ..Our results provide functional and mechanistic links between the oncoprotein Bmi-1 and the tumor suppressor PTEN in the development and progression of cancer...
  40. ncbi A paracrine requirement for hedgehog signalling in cancer
    Robert L Yauch
    Genentech Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nature 455:406-10. 2008
    ..Taken together, these studies demonstrate a paracrine requirement for Hh ligand signalling in the tumorigenesis of Hh-expressing cancers and have important implications for the development of Hh pathway antagonists in cancer...
  41. ncbi Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9
    Andrei V Krivtsov
    Division of Hematology Oncology, Children s Hospital, Boston, Massachusetts 02115, USA
    Nature 442:818-22. 2006
    ..Our findings define progression from normal progenitor to cancer stem cell, and suggest that targeting a self-renewal programme expressed in an abnormal context may be possible...
  42. ncbi Modeling of tumor growth and anticancer effects of combination therapy
    Gilbert Koch
    Department of Mathematics and Statistics, University of Konstanz, Germany
    J Pharmacokinet Pharmacodyn 36:179-97. 2009
    ..The unique feature of the presented approach is the ability to characterize the nature of combined drug interaction as well as to quantify the intensity of such interactions by assessing the time course of combined drug effect...
  43. ncbi Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells
    David C Taussig
    Department of Medical Oncology, St Bartholomew s Hospital, London, UK
    Blood 112:568-75. 2008
    ..More importantly, the work suggests that there is greater variation in the phenotypes of leukemia-initiating cells than previously suggested...
  44. ncbi Reprogramming metastatic tumour cells with embryonic microenvironments
    Mary J C Hendrix
    Cancer Biology and Epigenomics Program, Children s Memorial Research Centre, Robert H Lurie Comprehensive Cancer Centre, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60614, USA
    Nat Rev Cancer 7:246-55. 2007
    ..This Review will summarize the embryonic models used to reverse the metastatic melanoma phenotype, and highlight the prominent signalling pathways that have emerged as noteworthy targets for future consideration...
  45. ncbi A new model of patient tumor-derived breast cancer xenografts for preclinical assays
    Elisabetta Marangoni
    U612 Institut National de la Sante et de la Recherche Medicale, Pharmacologie Préclinique Antitumorale, Paris Anatomie et Cytologie Pathologique, Hopital Trousseau, Tours, France
    Clin Cancer Res 13:3989-98. 2007
    ..To establish a panel of human breast cancer (HBC) xenografts in immunodeficient mice suitable for pharmacologic preclinical assays...
  46. ncbi Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo
    Simone Fulda
    University Children s Hospital, Ulm, Germany
    Nat Med 8:808-15. 2002
    ..Thus, Smac agonists are promising candidates for cancer therapy by potentiating cytotoxic therapies...
  47. ncbi Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line
    Massimiliano Cariati
    Department of Academic Oncology, King s College London and Guy s and St Thomas NHS Foundation Trust, United Kingdom
    Int J Cancer 122:298-304. 2008
    ..These findings support the existence of a highly tumourigenic sub-population in breast cancer cells. Furthermore, it shows alpha6-integrin as a potential therapeutic target aimed at tumour-generating subsets of breast cancer cells...
  48. pmc Gamma delta T cells provide an early source of interferon gamma in tumor immunity
    Yunfei Gao
    Section of Rheumatology, Yale School of Medicine, 300 Cedar Street, CAB Building Room S517, New Haven, CT 06520, USA
    J Exp Med 198:433-42. 2003
    ..These results demonstrate that gammadelta T cells can play a necessary role in tumor immunity through provision of an early source of IFN-gamma that in turn may regulate the function of tumor-triggered alphabeta T cells...
  49. pmc The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling
    Douglas S Micalizzi
    Program in Molecular Biology, University of Colorado School of Medicine, Aurora, Colorado 80045, USA
    J Clin Invest 119:2678-90. 2009
    ..Our findings indicate that Six1, acting through TGF-beta signaling and EMT, is a powerful and global promoter of cancer metastasis...
  50. ncbi The fate of human malignant melanoma cells transplanted into zebrafish embryos: assessment of migration and cell division in the absence of tumor formation
    Lisa M J Lee
    Children s Memorial Research Center, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60614 3394, USA
    Dev Dyn 233:1560-70. 2005
    ..These results demonstrate the utility of the zebrafish embryonic model for the study of tumor cell plasticity and suggest that this experimental paradigm can be a powerful one in which to investigate tumor-microenvironment interactions...
  51. pmc HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer
    Merel Gijsen
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    PLoS Biol 8:e1000563. 2010
    ..Our results may also have implications for resistance to other therapies targeting HER receptors...
  52. ncbi The roles of IFN gamma in protection against tumor development and cancer immunoediting
    Hiroaki Ikeda
    Department of Pathology and Immunology, Center for Immunology, School of Medicine, Washington University, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Cytokine Growth Factor Rev 13:95-109. 2002
    ....
  53. ncbi Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells
    Julie Lessard
    Laboratory of Molecular Genetics of Hemopoietic Stem Cells, Clinical Research Institute of Montreal, 110 Pine Avenue West, Montreal, Quebec, Canada, H2W 1R7
    Nature 423:255-60. 2003
    ..Complementation studies showed that Bmi-1 completely rescues these proliferative defects. These studies therefore indicate that Bmi-1 has an essential role in regulating the proliferative activity of both normal and leukaemic stem cells...
  54. ncbi Single-vector inducible lentiviral RNAi system for oncology target validation
    Dmitri Wiederschain
    Oncology Research, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, USA
    Cell Cycle 8:498-504. 2009
    ..The versatile and robust inducible lentiviral RNAi system reported herein can therefore serve as a powerful tool to rapidly reveal tumor cell dependence...
  55. ncbi Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells
    Max G Bachem
    Department of Clinical Chemistry, University of Ulm, D 89070 Ulm, Germany
    Gastroenterology 128:907-21. 2005
    ..The aims of this study were to examine the cellular and molecular mechanisms of fibrogenesis associated with pancreatic adenocarcinomas...
  56. ncbi PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
    J Li
    Department of Pathology, College of Physicians and Surgeons, Columbia University, 630 West 168 Street, New York, NY 10032, USA
    Science 275:1943-7. 1997
    ..These homologies suggest that PTEN may suppress tumor cell growth by antagonizing protein tyrosine kinases and may regulate tumor cell invasion and metastasis through interactions at focal adhesions...
  57. ncbi Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic
    R M Hoffman
    AntiCancer, Inc, San Diego, CA 92111, USA
    Invest New Drugs 17:343-59. 1999
    ..These unique SOI models have been used for innovative drug discovery and mechanism studies and serve as a bridge linking pre-clinical and clinical research and drug development...
  58. ncbi The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis
    Qihong Huang
    The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
    Nat Cell Biol 10:202-10. 2008
    ..Taken together, our findings indicate that miRNAs are involved in tumour migration and invasion, and implicate miR-373 and miR-520c as metastasis-promoting miRNAs...
  59. pmc Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth
    Keiichi Kondo
    Department of Adult Oncology, Dana Farber Cancer Institute and Brigham and Womens Hospital, Harvard Medical School, Boston, Massachusetts, USA
    PLoS Biol 1:E83. 2003
    ..These results establish that tumor suppression by pVHL is linked to regulation of HIF target genes...
  60. pmc Angiogenesis-independent tumor growth mediated by stem-like cancer cells
    Per Ø Sakariassen
    NorLux NeuroOncology, Department of Biomedicine, University of Bergen, N 5020 Bergen, Norway
    Proc Natl Acad Sci U S A 103:16466-71. 2006
    ..This article underlines the need for developing therapies that specifically target the stem-like cell pools in tumors...
  61. ncbi CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells
    Z Qin
    Max Delbruck Center for Molecular Medicine, Berlin, Germany
    Immunity 12:677-86. 2000
    ..This shows that an effective anti-tumor response involves communication between CD4+ T cells and nonhematopoietic cells, most likely within the tumor stroma, and that tumor immunity must not entirely rely on direct tumor cell killing...
  62. ncbi Side population cells isolated from mesenchymal neoplasms have tumor initiating potential
    Colleen Wu
    Program in Developmental and Stem Cell Biology, Toronto Medical Discovery Tower, Hospital for Sick Children, Toronto, ON, Canada
    Cancer Res 67:8216-22. 2007
    ..In addition, our data suggest that the proportion of SP cells could be used as a prognostic factor and that therapeutically targeting this subpopulation of cells could be used to improve patient outcome...
  63. ncbi Involvement of chemokine receptors in breast cancer metastasis
    A Muller
    Department of Immunology, DNAX Research Institute, Palo Alto, California 94304, USA
    Nature 410:50-6. 2001
    ..Our findings indicate that chemokines and their receptors have a critical role in determining the metastatic destination of tumour cells...
  64. ncbi The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis
    J Oh
    Department of Molecular Oncology, Kyoto University Graduate School of Medicine, 606 8501, Kyoto, Japan
    Cell 107:789-800. 2001
    ..These results support a role for RECK in the regulation of MMP-2 in vivo and implicate RECK downregulation in tumor angiogenesis...
  65. ncbi Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer
    Jindan Yu
    Department of Pathology, Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Cancer Cell 12:419-31. 2007
    ..Taken together, we demonstrate the power of integrating multiple diverse genomic data to decipher targets of disease-related genes...
  66. pmc Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery
    D D Fang
    Department of Protein Therapeutics, Celera, Inc, Rockville, MD 20850, USA
    Br J Cancer 102:1265-75. 2010
    ..Additional validation of the CSC properties of tumour spheres would support their use as CSC models and provide an opportunity to discover additional CSC cell surface markers to aid in CSC detection and potential elimination...
  67. ncbi Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer
    Lakshmi Sampath
    Division of Molecular Imaging, Department of Radiology, Baylor College of Medicine, Houston, TX 77030, USA
    J Nucl Med 48:1501-10. 2007
    ..The stoichiometric ratios "n" and "m" refer to the number of diethylenetriaminepentaacetic acid dianhydride (DTPA) and IRDye 800CW molecules bound per trastuzumab molecule, respectively...
  68. ncbi Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells
    Shunsuke Fukumoto
    Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Kyushu University, 1 1 Maidashi 3 chome, Higashi ku, Fukuoka 812 8582, Japan
    Clin Exp Metastasis 22:31-8. 2005
    ..These findings suggested that endostatin inhibited lymphangiogenesis and lymph node metastasis by suppressing the production of VEGF-C in tumor cells...
  69. ncbi Transendothelial function of human metastatic melanoma cells: role of the microenvironment in cell-fate determination
    Mary J C Hendrix
    Department of Anatomy and Cell Biology, University of Iowa, 51 Newton Road, 1 100 BSB, Iowa City, IA 52242, USA
    Cancer Res 62:665-8. 2002
    ....
  70. pmc Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme
    Caterina Giannini
    Departments of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Neuro Oncol 7:164-76. 2005
    ..The fact that such studies were carried out by using an invasive tumor model in an anatomically appropriate context should ensure a rigorous preclinical assessment of agent efficacy...
  71. ncbi Human melanoma cells transplanted into zebrafish proliferate, migrate, produce melanin, form masses and stimulate angiogenesis in zebrafish
    Maryann Haldi
    Phylonix Pharmaceuticals, Inc, 100 Inman Street, Suite 300, Cambridge, MA 02139, USA
    Angiogenesis 9:139-51. 2006
    ..The zebrafish model offers a rapid efficient approach for assessing human cancer cells at various stages of tumorigenesis...
  72. ncbi Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
    F M Sirotnak
    Department of Medicine and Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 6:4885-92. 2000
    ..They also suggest significant clinical benefit from ZD1839 in combination with a variety of widely used cytotoxic agents...
  73. ncbi IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity
    V Shankaran
    Department of Pathology and Immunology, Center for Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA
    Nature 410:1107-11. 2001
    ..However, this process also leads to the immunoselection of tumour cells that are more capable of surviving in an immunocompetent host, which explains the apparent paradox of tumour formation in immunologically intact individuals...
  74. ncbi A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia
    G G Wulf
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Blood 98:1166-73. 2001
    ..They also suggest a mechanism by which SP cells could escape the effects of cytostatic drugs and might eventually contribute to leukemia relapse. (Blood. 2001;98:1166-1173)..
  75. ncbi Targeting hypoxia cell signaling for cancer therapy
    Giovanni Melillo
    Developmental Therapeutics Program, SAIC Frederick, Inc, National Cancer Institute, Frederick, MD 21702, USA
    Cancer Metastasis Rev 26:341-52. 2007
    ..A rational development plan aimed to validate target inhibition in preclinical models and early clinical trials is essential for a rapid translation of these agents to the treatment of human cancers...
  76. ncbi Tumor growth need not be driven by rare cancer stem cells
    Priscilla N Kelly
    Walter and Eliza Hall Institute of Medical Research, Melbourne 3050, Australia
    Science 317:337. 2007
    ..We suggest that the low frequency of tumor-sustaining cells observed in xenotransplantation studies may reflect the limited ability of human tumor cells to adapt to growth in a foreign (mouse) milieu...
  77. ncbi Leukemia-initiating cells in human T-lymphoblastic leukemia exhibit glucocorticoid resistance
    Priscilla P L Chiu
    Developmental and Stem Cell Biology, Hospital for Sick Children, Toronto, ON, Canada
    Blood 116:5268-79. 2010
    ..Our results establish that primary CD1a(-) T-ALL cells are functionally distinct from CD1a(+) cells and that the CD7(+)CD1a(-) subset is enriched for L-IC activity that may be involved in mediating disease relapse after therapy...
  78. ncbi Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice
    Erika Cretney
    Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Institute, A Beckett Street, East Melbourne, 8006 Victoria, Australia
    J Immunol 168:1356-61. 2002
    ..TRAIL gene-targeted mice were also more sensitive to the chemical carcinogen methylcholanthrene. These results substantiated TRAIL as an important natural effector molecule used in the host defense against transformed cells...
  79. ncbi The tumor macroenvironment and systemic regulation of breast cancer progression
    Zafira Castaño
    Department of Medicine, Hematology Division, Brigham and Women s Hospital, Harvard Medical School, 1 Blackfan Circle, Boston, MA 02115, USA
    Int J Dev Biol 55:889-97. 2011
    ..In this review, we address the systemic, or "macroenvironmental", contribution to tumor initiation and progression and what is known about how a pro-tumorigenic systemic environment is established...
  80. pmc Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer
    Dong Liang Chen
    State Key Laboratory of Oncology in South China
    Carcinogenesis 34:803-11. 2013
    ..Taken together, these results demonstrated that overexpression of PXN induced by suppression of miR-137 promotes tumor progression and metastasis and could serve as an independent prognostic indicator in CRC patients...
  81. ncbi Cytohesins are cytoplasmic ErbB receptor activators
    Anke Bill
    LIMES Institute, Program Unit Chemical Biology and Medicinal Chemistry, Laboratory of Chemical Biology, Rheinische Friedrich Wilhelms Universitat Bonn, Gerhard Domagk Str 1, 53121 Bonn, Germany
    Cell 143:201-11. 2010
    ..Our results establish cytohesins as cytoplasmic conformational activators of ErbB receptors that are of pathophysiological relevance...
  82. pmc Establishment and characterization of a primary human chordoma xenograft model
    I Mei Siu
    Department of Neurosurgery, The Johns Hopkins University, Baltimore, MD, USA
    J Neurosurg 116:801-9. 2012
    ..Currently, there are only a few established chordoma cell lines and no primary xenograft model. In this study, the authors aimed to develop a primary chordoma xenograft model...
  83. ncbi Quantified tumor t1 is a generic early-response imaging biomarker for chemotherapy reflecting cell viability
    Paul M J McSheehy
    Oncology Research and Global Imaging Group, Novartis Institutes for BioMedical Research, Basel, Switzerland
    Clin Cancer Res 16:212-25. 2010
    ..Identification of a generic response biomarker by comparison of chemotherapeutics with different action mechanisms on several noninvasive biomarkers in experimental tumor models...
  84. ncbi Transgenic Polyoma middle-T mice model premalignant mammary disease
    J E Maglione
    Department of Medicine, Cancer Center, School of Medicine, University of California-San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
    Cancer Res 61:8298-305. 2001
    ..These results support the use of PyV-mT transgenic mice as a model for investigating the multistep progression of malignant mammary tumorigenesis and metastasis...
  85. pmc Key roles for the lipid signaling enzyme phospholipase d1 in the tumor microenvironment during tumor angiogenesis and metastasis
    Qin Chen
    Department of Pharmacological Sciences and Center for Developmental Genetics, Stony Brook University, Stony Brook, NY 11794 5140, USA
    Sci Signal 5:ra79. 2012
    ....
  86. ncbi Self-renewal gene tracking to identify tumour-initiating cells associated with metastatic potential
    C Y Darini
    CNRS, Institute of Biology Development and Cancer, University of Nice Sophia Antipolis, 28 Avenue de Valombrose, Nice Cedex 2, France
    Oncogene 31:2438-49. 2012
    ..Consequently, it provides an appropriate model to develop novel therapies aiming to strike down TICs by targeting self-renewal genes, therefore efficient to reduce tumour growth and metastatic disease...
  87. ncbi Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells
    Lubna Patrawala
    Department of Carcinogenesis, The University of Texas M D Anderson Cancer Center, Science Park Research Division, 1808 Park Road 1C, Smithville, TX 78957, USA
    Cancer Res 67:6796-805. 2007
    ..These observations together suggest that prostate cancer cells are organized as a hierarchy...
  88. ncbi L1 cell adhesion molecule is a novel therapeutic target in intrahepatic cholangiocarcinoma
    Jeong Ki Min
    Therapeutic Antibody Research Center, Korea Research Institute of Bioscience and Biotechnology, Chungnam National University School of Medicine, Daejon, Korea
    Clin Cancer Res 16:3571-80. 2010
    ..Intrahepatic cholangiocarcinoma (ICC), a highly malignant hepatobiliary cancer, has a poor prognosis and is refractory to conventional therapies. The aim of this study is to discover a novel molecular target for the treatment of ICC...
  89. pmc The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration
    Jichao Qin
    Department of Molecular Carcinogenesis, University of Texas M D Anderson Cancer Center, Science Park, Smithville, TX 78957, USA
    Cell Stem Cell 10:556-69. 2012
    ..Altogether, our study suggests that PSA(-/lo) cells may represent a critical source of castration-resistant PCa cells...
  90. ncbi Identification of T-lymphocytic leukemia-initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease
    Ruth M Risueno
    Stem Cell and Cancer Research Institute, McMaster University, Hamilton, ON, USA
    Blood 117:7112-20. 2011
    ..These findings have implications both for the basic biology of CSC function, and for the use of in vivo models of the leukemogenic process in preclinical or diagnostic studies...
  91. ncbi Active site mutant dimethylarginine dimethylaminohydrolase 1 expression confers an intermediate tumour phenotype in C6 gliomas
    Jessica Kr Boult
    CRUK and EPSRC Cancer Imaging Centre, The Institute of Cancer Research and Royal Marsden NHS Trust, Sutton, Surrey, UK
    J Pathol 225:344-52. 2011
    ..DDAH1 is an important mediator of tumour progression, but appears to have addition roles independent of its metabolism of ADMA, which need to be considered in therapeutic strategies targeted against the NO/DDAH pathway in cancer...
  92. pmc Novel in vivo model of inducible multi-drug resistance in acute lymphoblastic leukemia with chromosomal translocation t(4;11)
    Susan J Zunino
    United States Department of Agriculture, Agricultural Research Service, Western Human Nutrition Research Center, 430 West Health Sciences Drive, Davis, CA 95616, United States
    Cancer Lett 296:49-54. 2010
    ..These data describe a novel inducible model for investigating multi-drug resistance mechanisms in high-risk t(4;11) ALL...
  93. pmc High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias
    S Morisot
    Department of Pediatrics, Center for Stem Cell Biology and Regenerative Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Leukemia 24:1859-66. 2010
    ..This very high frequency of LSCs suggests that a hierarchical LSC model is not valuable for poor-outcome ALL...
  94. pmc Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia
    Richard T Williams
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Genes Dev 21:2283-7. 2007
    ..Hence, salutary cytokines in the hematopoietic microenvironment can facilitate leukemic proliferation and confer resistance to targeted therapy...
  95. ncbi Brief report: a bioassay to identify primary human prostate cancer repopulating cells
    Roxanne Toivanen
    Prostate and Breast Cancer Research Group, Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia
    Stem Cells 29:1310-4. 2011
    ..Thus, this new protocol efficiently established tumors and enabled proliferative expansion of both intact tumor tissue and fractionated cancer cells, providing a bioassay to identify and therapeutically target PCa repopulating cells...
  96. pmc Water permeability through aquaporin-4 is regulated by protein kinase C and becomes rate-limiting for glioma invasion
    E S McCoy
    Department of Neurobiology and Center for Glial Biology in Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Neuroscience 168:971-81. 2010
    ..AQP4 expressing glioma cells showed significantly reduced invasion compared to AQP1 and S180 expressing tumors as determined by quantitative stereology, consistent with a differential role for AQP1 and AQP4 in this process...
  97. ncbi Multimodality imaging of IL-18--binding protein-Fc therapy of experimental lung metastasis
    Qizhen Cao
    The Molecular Imaging Program at Stanford, Department of Radiology and Bio X Program, Stanford University School of Medicine, 1201 Welch Road, Stanford, CA 94305, USA
    Clin Cancer Res 14:6137-45. 2008
    ....
  98. ncbi A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy
    Si Tuen Lee-Hoeflich
    Department of Pathology, Genentech, Inc, South San Francisco, CA 94080, USA
    Cancer Res 68:5878-87. 2008
    ....
  99. ncbi Direct orthotopic transplantation of fresh surgical specimen preserves CD133+ tumor cells in clinically relevant mouse models of medulloblastoma and glioma
    Qin Shu
    Laboratory of Molecular Neuro Oncology, Texas Children s Cancer Center, Texas Children s Hospital, 6621 Fannin St, MC 3 3320, Houston, Texas 77030, USA
    Stem Cells 26:1414-24. 2008
    ..Disclosure of potential conflicts of interest is found at the end of this article...
  100. ncbi Blocking tumor growth, invasion, and metastasis by maspin in a syngeneic breast cancer model
    H Y Shi
    Baylor College of Medicine, Department of Molecular and Cellular Biology, Houston, Texas 77030, USA
    Cancer Res 61:6945-51. 2001
    ..Thus, maspin can block primary tumor growth as well as invasion and metastasis. These data support the concept that maspin has a strong protective role against tumor progression...
  101. ncbi Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells
    Omer H Yilmaz
    Howard Hughes Medical Institute, Life Sciences Institute, Department of Internal Medicine, and Center for Stem Cell Biology, University of Michigan, Ann Arbor, Michigan 48109 2216, USA
    Nature 441:475-82. 2006
    ..Mechanistic differences between normal stem cells and cancer stem cells can thus be targeted to deplete cancer stem cells without damaging normal stem cells...

Research Grants82

  1. Plasmalogen Metabolism by iPLA2 in Ischemic Myocardium
    Jane McHowat; Fiscal Year: 2005
    ..Our long-term objectives are to determine the metabolic pathways that are appropriate targets for novel therapeutic strategies to alleviate the morbidity and mortality of ischemic heart disease in man. ..
  2. Non-Viral Vectors for Liver Gene Transfer
    Feng Liu; Fiscal Year: 2006
    ..The therapeutic effects on the metabolic disease on phenylketonuria (PKU) mice, will be examined after the PAH gene transfer using the approach in this proposal. ..
  3. Adenoviral GFP targeting of metastatic human tumors using multiple delivery route
    Hiroyuki Kishimoto; Fiscal Year: 2008
    ..Having obtained these results, we can move forward in the Phase II grant application with experiments to bring OBP-401 to the clinic for use in cancer surgery in human patients. [unreadable] [unreadable] [unreadable]..
  4. Imageable tumor-targeting bacteria
    Ming Zhao; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  5. Dual-color tumor-host imaging models
    Meng Yang; Fiscal Year: 2007
    ..These models have significant commercial potential for discovery and development of stroma-targeted and anti-angiogenesis drugs. [unreadable] [unreadable] [unreadable]..
  6. Therapeutic hair follicle-derived neurospheres
    Meng Yang; Fiscal Year: 2007
    ..Human hair- follicle bulge cells will be further characterized and developed for therapeutic potential for nerve regeneration in Phase III. [unreadable]..
  7. Orthotopic models of tumor angiogenesis and blood flow
    Meng Yang; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  8. RHOMOCYCSTEINASE FOR HOMOCYSTEINE ASSAY
    Yuying Tan; Fiscal Year: 2002
    ..The tHCY enzymatic kits for these applications will be ready for commercial launch at this point. PROPOSED COMMERCIAL APPLICATION: Not Available ..
  9. MTOR as a Therapeutic Target in Childhood Cancer
    Peter Houghton; Fiscal Year: 2005
    ..abstract_text> ..
  10. Targeted tumoricidal bacteria
    Ming Zhao; Fiscal Year: 2007
    ..Future human trials of the tumor-killing bacteria can be held after the Phase I and Phase II grant periods are completed. [unreadable] [unreadable] [unreadable]..
  11. Inhibitors of 5alpha-reductase for acne therapy
    Lingna Li; Fiscal Year: 2002
    ..PROPOSED COMMERCIAL APPLICATIONS: Liposomal 4-MA will be developed as a topical selectively targeted therapeutic for acne for which they should be a very market. ..
  12. Discovery of novel fluorescent reporter genes
    Ming Zhao; Fiscal Year: 2004
    ..Reporters with spectral properties that can be used for whole-body imaging of tumors in the lung and their metastases will be candidates for further development for numerous applications of multi-color imaging. ..
  13. Enzyme therapy for hyperhomocysteinemia
    Yuying Tan; Fiscal Year: 2005
    ..Phase II results will lead to an IND for MEGC-PEG-rMETase for end stage renal disease patients and other patients with intractable hyperhomocysteinemia and high cardiovascular disease mortality. ..
  14. Omega-3 fat to reduce risk for breast cancer
    WANDA ELAINE HARDMAN; Fiscal Year: 2010
    ....
  15. IAPs As Novel Targets for Cancer Therapy
    Lily Yang; Fiscal Year: 2007
    ..Results from this research should allow us to determine if IAPs are novel molecular targets for the development of cancer-specific therapeutic approaches. ..
  16. RAIT of Pancreatic Cancer with Humanized PAM4
    ROBERT SHARKEY; Fiscal Year: 2005
    ..The trial will be conducted at the Garden State Cancer Center and Johns Hopkins University School of Medicine. CMMI will be responsible for monitoring the study's progress. ..
  17. N-3 fatty acid & binding protein MRG on mammary tumor
    YUENIAN SHI; Fiscal Year: 2006
    ..These studies will help to identify MRG as mediator for differentiation for mammary gland and for interaction with n-3 PUPA on inhibition of mammary tumorigenesis. ..
  18. Correlative Imaging of Tumor Angiogenesis
    Sanjiv Gambhir; Fiscal Year: 2004
    ..We plan to perform pharmacokinetics and toxicology studies with preclinical materials and prepare an agent for gamma and SPECT imaging in clinical studies and file an IRB for cancer angiogenesis evaluation. ..
  19. MoAbs for the Management of Pancreatic Cancer
    David Gold; Fiscal Year: 2005
    ..Finally, a PAM4IL2 fusion protein will be examined for its ability to enhance tumor uptake of a subsequently administered radiolabeled PAM4 antibody. ..
  20. Progesterone regulation of human luteal cell viability
    John Peluso; Fiscal Year: 2006
    ..Such selective manipulation of the P4's actions could have far reaching effects on the treatment for infertility, contraception and certain types of cancers. [unreadable] [unreadable]..
  21. ROLES OF NITRIC OXIDE AND OXYGEN IN OCULAR MELANOMA
    RODNEY BRAUN; Fiscal Year: 2002
    ....
  22. MECHANISMS FOR CHEMOPREVENTION OF COLON CANCER
    CHINTHALAPALLY RAO; Fiscal Year: 2004
    ..Tissue distribution and comparative metabolism studies of curcumin and PEMC will be studied with synthetic [3H] curcumin and [3H]-PEMC in vivo in male F-344 rats. ..
  23. Pretargeting mouse tumor with anti-PSMA antibody-MORF
    Guozheng Liu; Fiscal Year: 2005
    ..Based on our experiences in this pretargeting strategy, we are confident that these investigations on the pretargeting imaging of prostate cancer models with MORFs will be successful. ..
  24. Development of Digital SNP Analysis in Cancer Detection
    Ie Ming Shih; Fiscal Year: 2005
    ..Thus, the encouraging results from this study will ensure the detection of AI in plasma a promising cancer research direction for further exploration. ..
  25. Preclin. model for prevention of NSCLC in former smokers
    HILDEGARD SCHULLER; Fiscal Year: 2006
    ....
  26. 9/10TH Conf./Cancer Therapy/Antibody/Immunoconjugates
    David Goldenberg; Fiscal Year: 2004
    ..The conference chairman, Dr. Goldenberg, has secured two outstanding scientists as co-chairmen, Drs. Ralph Reisfeld (Scripps) and Edward Sausville (NCI). ..
  27. CMMI Human Subject Research Enhancement Program
    David Goldenberg; Fiscal Year: 2002
    ..3.) Provide travel expenses and educational materials for IRB members, investigators, and Regulatory Affairs Office personnel to attend meetings for educational enhancement. ..
  28. Uveal Melanoma Micrometastasis
    Pierre L Triozzi; Fiscal Year: 2010
    ..Micrometastases, microscopic deposits of tumor that have spread via the bloodstream, are present in many patients with uveal melanoma at diagnosis. This project will test new methods of identifying and inhibiting these deposits. ..
  29. ADENOVIRUS E3 PROTEINS AND TUMOR NECROSIS FACTOR
    William Wold; Fiscal Year: 2001
    ....
  30. YELLOW FEVER 17D-BASED CHIMERIC FLAVIVIRUS VACCINES
    William Wold; Fiscal Year: 2002
    ....
  31. NEUROCHEMISTRY OF NOCICEPTION
    Patrick Mantyh; Fiscal Year: 2002
    ....
  32. CTGF in Pancreatic Tumor Growth
    Amato J Giaccia; Fiscal Year: 2010
    ..In summary, the proposed studies are intended to address an important mechanism by which CTGF affects tumor progression in pancreatic cancers and to determine how effective it is in combination therapy to bring it to the clinic. ..
  33. AAV-Based Plasmacytoid Dendritic Cell Cancer Vaccine
    Pierre L Triozzi; Fiscal Year: 2010
    ....
  34. Hamster Model for Oncolytic Adenovirus Vectors
    WILLIAM SM WOLD; Fiscal Year: 2010
    ..Although not proposed specifically in this application, these studies should also provide novel information on adenovirus pathogenesis. ..
  35. Peptide Derivatives to treat Urinary Tract Infections
    Laszlo Otvos; Fiscal Year: 2003
    ..Our hope is that by the end of the grant period, we will be able to provide a pyrrhocoricin-derived peptide for ensuing US Food and Drug Administration-approved preclinical and clinical evaluation against urinary tract infections. ..
  36. Bispecific Antibody Pretargeted Therapy of Pancreatic Cancer
    ROBERT SHARKEY; Fiscal Year: 2008
    ..Overall, these studies will assist in establishing whether this type of pretargeting approach could have a role in the clinical management of pancreatic cancer. [unreadable] [unreadable] [unreadable]..
  37. Syrian Hamster as a Permissive Model for Testing Anti-Adenovirus Drugs
    William Wold; Fiscal Year: 2007
    ..Success in this project could lead to the eventual approval of drugs to treat adenovirus infections in immunosuppressed patients. [unreadable] [unreadable] [unreadable]..
  38. Intrnational Clubfoot Symposium
    Jose Morcuende; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  39. DETERMINANTS OF TISSUE ESTRADIOL SENSITIVITY
    Richard Santen; Fiscal Year: 2009
    ..FTS, a novel mTOR inhibitor will be used in vitro to activate the stress kinase pathway and apoptosis. In vivo, FTS will be used to enhance estradiol induced apoptosis in nude mice. ..
  40. Mechanisms of chemopreventive effect of resveratrol
    Zigang Dong; Fiscal Year: 2009
    ..Our long-term goal is to identify the molecular mechanism explaining the anti-tumor effect exhibited by resveratrol. Such knowledge will help in developing better chemopreventive agents with fewer side effects. ..
  41. Pathogenic Mechanism of Polycystic Kidney Disease
    Yumay Chen; Fiscal Year: 2010
    ..Our studies will provide novel insight into the molecular pathogenesis of PKD. They will help explain why cysts progress at different rates and how therapies to slow the progression of PKD can be designed rationally. ..
  42. Molecular Basis of Flavivirus Neurovirulence
    William Wold; Fiscal Year: 2007
    ..abstract_text> ..
  43. Multimodality Imaging of Cell Mediated Gene Transfer
    Sanjiv Gambhir; Fiscal Year: 2007
    ..Furthermore, the methodologies developed in this proposal will help other investigators to implement various models in which imaging of cell survival and cardiac gene therapy are important. [unreadable] [unreadable] [unreadable]..
  44. Cancer Pain and Breast Tumor Metastasis to Bone
    Patrick Mantyh; Fiscal Year: 2007
    ..Information from these investigations should expand our understanding of the mechanisms that generate and maintain bone cancer pain and lead to the development of more effective therapies for treating bone cancer pain. ..
  45. Molecular basis of arsenic-induced cell transformation
    Zigang Dong; Fiscal Year: 2007
    ..Such knowledge will facilitate the design of more effective and specific strategies with fewer side effects for chemoprevention of arsenic-induced cancer. ..
  46. LIGHT DURING DARKNESS AND BREAST CANCER PROGRESSION
    David Blask; Fiscal Year: 2004
    ....
  47. Role of Fas/NF kB in H.pylori induced gastric carcinoma
    JeanMarie Houghton; Fiscal Year: 2003
    ..Defining the regulation of these pathways will help define the complex relationship helicobacter shares with its host. ..
  48. Inhibition of Fas-apoptosis in Gastric Cancer
    JeanMarie Houghton; Fiscal Year: 2010
    ..These studies will provide critical insight into novel preventive, and anti-cancer strategies aimed at restoring Fas sensitivity within tumor cells and provide a new direction for cancer treatment. ..
  49. Tumor suppressor gene at 6q in adenoid cystic carcinoma
    Christopher Moskaluk; Fiscal Year: 2006
    ..Since AGO appears to have a smaller number of genetic changes than these other malignancies, it may serve as a simpler system to identify the 6q tumor suppressor gene. ..
  50. Ultrasound Monitoring of Rat Metastatic Uveal Melanoma
    RODNEY BRAUN; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  51. Enhancement of Ad-p53 Therapy with Intratumoral Taxane
    GEORGE YOO; Fiscal Year: 2004
    ..Favorable data from the proposed project will lead to the development of clinical trials using intratumoral and intra-wound injections of docetaxel and Ad-p53. ..
  52. Antifolate Resistance in Osteosarcoma
    Richard Gorlick; Fiscal Year: 2007
    ....
  53. Radiolabeled RGD Peptides for Breast Cancer Imaging and Therapy
    Zhen Cheng; Fiscal Year: 2010
    ..The same ligands labeled with therapeutic isotopes will allow targeted internal radiotherapy of integrin positive tumors. ..
  54. MINORITY PREDOCTORAL FELLOWSHIP PROGRAM
    HECTOR MOBINE; Fiscal Year: 2008
    ..The findings may not only afford further appreciation of the pathophysiology and etiology of peripartum cardiomyopathy but also of general mechanisms in disease progression. [unreadable] [unreadable] [unreadable]..
  55. Photons plus Ultrasound: Imaging and Sensing
    Lihong Wang; Fiscal Year: 2006
    ..unreadable] [unreadable] Previous critiques have been answered particularly as they addressed the participation of women and mechanisms to attract and reward students. [unreadable] [unreadable] [unreadable]..
  56. RARbeta in Melanoma: Epigenetic Regulation by Nutrients
    Richard Niles; Fiscal Year: 2007
    ..Depending on results obtained, this investigation can be translated into nutritional studies with animal models of melanoma. [unreadable] [unreadable] [unreadable]..
  57. Chemo/Antiretroviral therapy for HTLV-1 ATLL
    Lee Ratner; Fiscal Year: 2005
    ..abstract_text> ..
  58. Interaction of HIV gp120 & G protein coupled receptors
    Lee Ratner; Fiscal Year: 2007
    ..abstract_text> ..
  59. Third Generation Antiopportunistic Agents
    Aleem Gangjee; Fiscal Year: 2003
    ..Screening against tuberculosis (NIAID) and tumor cells in culture (NCI) is also proposed. ..
  60. Antitumor Antimitotics That Reverse Tumor Resistance
    Aleem Gangjee; Fiscal Year: 2010
    ..The study will also further define the mechanism of action of the novel series and could afford agents for clinical use. ..
  61. Single Agents with Designed Combination Chemotherapy Potential
    Aleem Gangjee; Fiscal Year: 2010
    ..abstract_text> ..
  62. Novel Bisphosphonates for Multiple Myeloma Therapy
    MONICA REINHOLZ; Fiscal Year: 2004
    ..Successful development of this new drug-design concept would provide a biologically and commercially superior approach for the treatment and prevention of skeletal-related complications of malignancy. ..
  63. Regulation of Proinflammatory Signaling Pathways in CFTR
    HARVEY BRUCE POLLARD; Fiscal Year: 2010
    ..The proposal is both unique and innovative by directing the investigation to the biology and chemistry of the IL-8 promoter in CF lung epithelial cells, both in vitro and in vivo. ..
  64. STRUCTURE BASED ANALOGS AS ANTIOPPORTUNISTIC AGENTS
    Aleem Gangjee; Fiscal Year: 2001
    ..The analogues synthesized will also be submitted for screening against tuberculosis (NIAID) parasitic diseases (WHO) and tumor cells in culture (NCI). ..
  65. NOVEL NONINDUCIBLE THYMIDYLATE SYNTHASE INHIBITORS
    Aleem Gangjee; Fiscal Year: 2004
    ....
  66. Development of Soluble FcR-Ig Fusion Proteins
    Leslie Johnson; Fiscal Year: 2004
    ..We believe that an FcR blockade would also be potentially useful in treating autoimmune hemolytic anemia, lupus, rheumatoid arthritis, Guillain-Barre syndrome and stiff man's syndrome. ..
  67. Novel Single, Dual and Multitargeted Inhibitors of RTKs
    Aleem Gangjee; Fiscal Year: 2007
    ..abstract_text> ..
  68. Novel Bisphosphonates for Breast Cancer Therapy
    MONICA REINHOLZ; Fiscal Year: 2002
    ..Proposed Commercial Application: Not Available. ..
  69. Alpha Folate Receptor Mediated GARFTase Inhibitors as Selective Antitumor Agents
    Aleem Gangjee; Fiscal Year: 2010
    ....
  70. FcRlll Blockade as a Treatment for Autoimmune Disease
    Leslie Johnson; Fiscal Year: 2004
    ..the studies outlined in this application will provide the basis for expanded production, characterization and further safety and efficacy studies of this molecule in small animals and primates, ultimately leading to human clinical trials ..
  71. Novel, P. jirovecii Specific Antipneumocystis Agents
    Aleem Gangjee; Fiscal Year: 2009
    ..These agents could be used alone or in combination to treat PCP thus providing novel agents against a new target. ..
  72. Imageable Mouse Models of Pancreatic Cancer
    Michael Bouvet; Fiscal Year: 2008
    ..Using such dual-colored imaging techniques, a better characterization of the tumor-host interactions in pancreatic cancer can be made. ..
  73. Changes in Functional Status Across Therapy for Primary Glioma
    Lee Jones; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  74. ENHANCEMENT OF HPV16 E6 & E7-SPECIFIC ANTITUMOR IMMUNITY
    T C Wu; Fiscal Year: 2001
    ..5) Perform head-to-head comparison of various E6, E7 and chimeric E6E7 vaccines in antitumor immunity using E6 and E7 expressing murine model tumors. ..
  75. PHYTOMELATONIN AND CANCER PREVENTION
    David Blask; Fiscal Year: 2004
    ....
  76. PREVENTIVE/THERAPEUTIC HPV VACCINE DEVELOPMENT
    T C Wu; Fiscal Year: 2003
    ..A.5 Evaluate the mechanisms of the anti-tumor immunity induced by vaccination. ..
  77. Protein Kinase G Regulation of Granulosa Cell Viability
    John Peluso; Fiscal Year: 2006
    ..We now propose to test this hypothesis using biochemical, genetic, imaging and cell biological techniques. [unreadable] [unreadable]..
  78. Regulation of Oocyte Viability by Granulosa Cell Contact
    John Peluso; Fiscal Year: 2004
    ..abstract_text> ..
  79. HYPOXIA AND GENE REPRESSION
    Amato Giaccia; Fiscal Year: 2009
    ..We will test these hypotheses through a combination of genetic and biochemical approaches in cell lines and in mice. ..
  80. Endothelial Regulation of T Cell Homing in Ovarian Carcinoma
    George Coukos; Fiscal Year: 2007
    ..Results obtained from the proposed studies will generate novel ideas for the development of molecular tools to circumvent impediments to tumor immunotherapy. ..
  81. Mutation of the Id1 gene in squamous cell cancer
    Jizhen Lin; Fiscal Year: 2005
    ..The study not only improves our understanding of the molecular mechanisms on the carcinogenesis and angiogenesis of SCC but also provides a foundation for innovative treatment against SCC in the future. ..